Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Cardiff Oncology (CRDF) reported a Q3 loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a $0.27 loss. This is a slight increase from the $0.22 loss per share reported a year ago.
November 08, 2024 | 12:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardiff Oncology reported a Q3 loss of $0.25 per share, better than the expected $0.27 loss, indicating a positive surprise in earnings performance.
The better-than-expected earnings loss suggests that Cardiff Oncology is performing slightly better than analysts anticipated, which could lead to a positive short-term impact on the stock price as investors react to the earnings beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100